News
12-30-2009, 09:10 AM
The aromatase inhibitor letrozole (Femara) produces a significant survival benefit over tamoxifen when used as adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer, according to updated results of a major trial released in a plenary session at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)...
More... (http://mnt.to/f/3vNw)
More... (http://mnt.to/f/3vNw)